The introduction of Herceptin, a Her2/neu extracellular domain-targeted therapeutic, to the marketplace has vastly improved outcome of patients with metastatic disease, as well as lowered recurrence rates and mortality in early-stage breast cancer [44]. Here, ERBB2 is linked to breast cancer.